Screener
ADMA Biologics ADMA Plasma Collection Centers — Sales & Marketing
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Research and development | 6,014 | - | 6,014 |
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
| Other income (expense), net | (20) | 150 | 130 |
| Income (loss) before taxes | 64,010 | (707) | 63,303 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's plasma collection centers — sales & marketing?
- ADMA Biologics (ADMA) reported plasma collection centers — sales & marketing of $0 in Q2 2026.
- What does plasma collection centers — sales & marketing mean?
- Includes costs incurred to attract plasma donors and promote the brand presence of collection centers within their local communities. This metric measures the efficiency of donor acquisition strategies and marketing outreach. High spending relative to revenue may indicate competitive pressure in the plasma collection market.
Ask your AI about ADMA Biologics's plasma collection centers — sales & marketing.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude